Seqker Biosciences
Seoul, South Korea· Est.
Seqker builds AI‑driven neoantigen vaccines and genomic diagnostics to deliver personalized oncology treatments.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Seqker builds AI‑driven neoantigen vaccines and genomic diagnostics to deliver personalized oncology treatments.
OncologyImmunology
Technology Platform
An integrated intelligent platform that combines matched tumor‑normal genomic sequencing, AI‑driven neoantigen prediction, and GMP manufacturing to create personalized cancer vaccines and diagnostic reports.
Opportunities
Successful Phase I data could attract strategic partnerships and enable expansion into later‑stage trials, while the platform’s diagnostic component offers additional revenue streams.
Risk Factors
Regulatory uncertainty for individualized vaccines, manufacturing scale‑up challenges, and intense competition from larger immuno‑oncology players.
Competitive Landscape
Seqker competes with BioNTech, Moderna, and NeoVax, differentiating itself through an end‑to‑end platform that integrates diagnostics, AI‑driven neoantigen selection, and in‑house GMP manufacturing.